REG - BSF Enterprise PLC - Result of Annual General Meeting

BSF EnterpriseAnnouncement

15/03/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230315:nRSO0890Ta&default-theme=true

RNS Number : 0890T  BSF Enterprise PLC  15 March 2023

15 March 2023

BSF Enterprise PLC

("BSF" or the "Company")

 

Result of Annual General Meeting

 

BSF Enterprise (LSE: BSFA), the Main Market listed biotech company and the
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to announce that at the Company's Annual General
Meeting held earlier today, all resolutions proposed were duly passed by
shareholders by way of a poll, the results of which were as follows:

 

 Resolution      Poll Results
         For     Against     Abstain  Discretionary  Total
 1       Shares  50,625,257  -        -              -      50,625,257
         %       100%        -        -              -      100%
 2       Shares  50,596,092  29,165   -              -      50,625,257
         %       99.94%      0.06%    -              -      100%
 3       Shares  50,596,092  29,165   -              -      50,625,257
         %       99.94%      0.06%    -              -      100%
 4       Shares  48,471,538  -        2,153,719      -      50,625,257
         %       95.75%      -        4.25%          -      100%
 5       Shares  50,596,092  -        29,165         -      50,625,257
         %       99.94%      -        0.06%          -      100%
 6       Shares  50,596,092  29,165   -              -      50,625,257
         %       99.94%      0.06%    -              -      100%
 7       Shares  50,596,092  -        29,165         -      50,625,257
         %       99.94%      -        0.06%          -      100%

 

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                              0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGNKPBPDBKDFND